Summary
18.06 -0.48(-2.59%)02/12/2026
Legend Biotech Corporation (LEGN)
LEGN reported last earnings on 2025-11-12 after the market. An EPS of $-0.11 was observed compared to an estimated EPS of $-0.13, resulting in a surprise value of $0.02. A revenue of $272 million was observed compared to an estimated revenue of $312 million, resulting in a surprise value of $-39 Million.
Legend Biotech Corporation (LEGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -2.59 | 2.22 | -12.39 | -19.78 | -2.16 | -33.91 | -2.97 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C- |
| Recommended Rating | Strong Sell |
| DCF | Strong Sell |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 18.06 | |
| Open | 18.05 | |
| High | 18.67 | |
| Low | 17.91 | |
| Volume | 1,975,397 | |
| Change | -0.48 | |
| Change % | -2.59 | |
| Avg Volume (20 Days) | 1,773,322 | |
| Volume/Avg Volume (20 Days) Ratio | 1.11 | |
| 52 Week Range | 26.91 - 45.30 | |
| Price vs 52 Week High | -60.13% | |
| Price vs 52 Week Low | -32.89% | |
| Range | 0.00 | |
| Gap Up/Down | -0.04 | |
Profitibility | ||
| Market Capitalization (Mln) | 2,914 | |
| Revenue per share | 10.0769 | |
| Net Income per share | -2.6574 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -6.7962 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
01/29 22:30 EST - seekingalpha.com
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings...
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings...
01/22 08:00 EST - 247wallst.com
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More
Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks were headed lower at the open, but as President Trump addressed the audience at the World Economic...
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More
Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks were headed lower at the open, but as President Trump addressed the audience at the World Economic...
01/14 13:46 EST - seekingalpha.com
Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12/27 05:03 EST - defenseworld.net
Connective Portfolio Management LLC Acquires New Holdings in Legend Biotech Corporation Sponsored ADR $LEGN
Connective Portfolio Management LLC bought a new stake in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 24,500 shares of...
Connective Portfolio Management LLC Acquires New Holdings in Legend Biotech Corporation Sponsored ADR $LEGN
Connective Portfolio Management LLC bought a new stake in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 24,500 shares of...
12/10 07:37 EST - gurufocus.com
First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe
Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job
First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe
Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job
12/06 14:00 EST - globenewswire.com
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4...
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4...
12/02 04:20 EST - defenseworld.net
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Ensign Peak Advisors Inc
Ensign Peak Advisors Inc trimmed its position in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 30.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,300 shares of the...
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Ensign Peak Advisors Inc
Ensign Peak Advisors Inc trimmed its position in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 30.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,300 shares of the...
11/25 14:38 EST - seekingalpha.com
Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?
Following Legend Biotech's solid financial results for Q3, its average PT rose to $74.90, which implies an upside of about 171.2% from its current stock price. Thanks to increased demand for its "gem" called Carvykti, adjusted net loss decreased by 55.2% to $18.8 million in Q3. A key reason for its...
Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?
Following Legend Biotech's solid financial results for Q3, its average PT rose to $74.90, which implies an upside of about 171.2% from its current stock price. Thanks to increased demand for its "gem" called Carvykti, adjusted net loss decreased by 55.2% to $18.8 million in Q3. A key reason for its...
11/13 12:08 EST - globenewswire.com
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation
11/12 12:51 EST - seekingalpha.com
Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript
Legend Biotech Corporation ( LEGN ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jessie Yeung - Vice President of Finance, Investor & Public Relations Ying Huang - CEO & Director Alan Bash - President of CARVYKTI® Carlos Santos - Chief Financial Officer Guowei Fang -...
Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript
Legend Biotech Corporation ( LEGN ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jessie Yeung - Vice President of Finance, Investor & Public Relations Ying Huang - CEO & Director Alan Bash - President of CARVYKTI® Carlos Santos - Chief Financial Officer Guowei Fang -...
11/03 11:05 EST - globenewswire.com
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN)...
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN)...
10/29 08:00 EST - globenewswire.com
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results.
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results.
10/06 13:29 EST - seekingalpha.com
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck...
09/09 23:47 EST - seekingalpha.com
Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Ying Huang - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst...
Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Ying Huang - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst...
08/18 08:00 EST - globenewswire.com
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie...
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie...
08/16 07:18 EST - seekingalpha.com
What Moved Markets This Week
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
What Moved Markets This Week
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
08/14 14:12 EST - seekingalpha.com
Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade
New Jersey based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with strong efficacy and double-digit sequential revenue growth, but Legend only receives a 50% revenue...
Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade
New Jersey based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with strong efficacy and double-digit sequential revenue growth, but Legend only receives a 50% revenue...
Market News
×
Loading news…